Sugi Predict

Sugi Predict / Compounds / SCHEMBL2582882

SCHEMBL2582882

SCHEMBL2582882

O=C(O)c1ccnc(C(F)(F)F)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ ASPH Q12797 2/20 0.44
▸ KDM8 Q8N371 2/20 0.44
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM5A P29375 2/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ KDM4A O75164 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ HIF1AN Q9NWT6 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ P2RX7 Q99572 7/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ XPO1 O14980 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29760859 1.00 KDM4E (0.44) KDM4EASPHKDM8HTTHSD17B10
SCHEMBL2576464 0.80 ATR (0.47) KDM4EP2RX7CYP2C19PSMD14
SCHEMBL1720696 0.80 ASPH (0.59) KDM4EASPHKDM8HTTHSD17B10
SCHEMBL29882303 0.80 ASPH (0.59) KDM4EASPHKDM8HTTHSD17B10
SCHEMBL25262538 0.79 KDM4E (0.44) KDM4EASPHKDM8HTTHSD17B10
SCHEMBL16099246 0.79 KDM4E (0.44) KDM4EASPHKDM8HTTHSD17B10
SCHEMBL22466622 0.76 L3MBTL1 (0.43) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL29272385 0.76 KDM5A (0.37) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL481041 0.76 NAPRT (0.55) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL15275295 0.75 SMN1; SMN2 (0.50) KDM4EASPHKDM8LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338243-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-06-24 — — US disclosed
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 — — US disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 — — CN disclosed
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
WO-2023039505-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2023-03-16 — — WO disclosed
CN-114829362-A Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatom and used as SHP2 inhibitor 成都倍特药业股份有限公司 2022-07-29 — — CN disclosed
US-20220235062-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-07-28 — — US disclosed
WO-2014152604-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
WO-2014152621-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
US-20140275056-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 — — EP disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 — — US disclosed
EP-2097416-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen, Inc (US) 2009-09-09 — — EP disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 — — US disclosed
WO-2008076425-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 — — WO disclosed
WO-2008018639-A2 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 — — WO disclosed
WO-2008018639-A2 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235062-A1 P2X7 MODULATORS P2RX7, P2RX4, P2RX1 KDM4E 4071/4885ASPH 2966/4885KDM8 3986/4885
US-20140275056-A1 P2X7 MODULATORS P2RX7, P2RX1, P2RX3 KDM4E 3568/4885ASPH 3586/4885KDM8 4284/4885
US-12338243-B2 P2X7 modulators P2RX7, P2RX4, P2RX1 KDM4E 4071/4885ASPH 2966/4885KDM8 3986/4885
US-11667634-B2 Inhibitors of RAF kinases BRAF, RAF1, NRAS KDM4E 2067/4885ASPH 4062/4885KDM8 1160/4885
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN KDM4E 99/4885ASPH 18/4885KDM8 30/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 KDM4E 680/4885ASPH 3697/4885KDM8 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.